Urogen Pharma (NASDAQ:URGN) Insider Sells $2,854,852.85 in Stock

Key Points

• Urogen Pharma insider Mark Schoenberg sold 60,677 shares at an average price of $47.05, generating $2.85 million. His remaining stake fell by 50.66% to 59,086 shares, following several earlier sales.
• URGN shares declined 1.5% to $46.16 but remain near their 52-week high of $50.81, with a market capitalization of approximately $2.26 billion.
• The company’s latest quarterly revenue of $72.46 million exceeded estimates, though its adjusted loss of $0.28 per share missed expectations. Analysts maintain a “Moderate Buy” consensus with an average price target of $50.38.

Urogen Pharma (NASDAQ:URGN - Get Free Report) insider Mark Schoenberg sold 60,677 shares of the business's stock in a transaction on Thursday, August 20th. The stock was sold at an average price of $47.05, for a total value of $2,854,852.85. Following the sale, the insider owned 59,086 shares in the company, valued at $2,779,996.30. This represents a 50.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total value of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $35.01, for a total transaction of $350,100.00.
• On Monday, June 8th, Mark Schoenberg sold 5,222 shares of Urogen Pharma stock. The stock was sold at an average price of $27.30, for a total transaction of $142,560.60.

Urogen Pharma Trading Down 1.5%

NASDAQ URGN traded down $0.70 during trading hours on Monday, hitting $46.16. 849,674 shares of the company's stock were exchanged, compared to its average volume of 817,922. Urogen Pharma has a 1-year low of $15.86 and a 1-year high of $50.81. The stock has a 50-day simple moving average of $40.51 and a 200 day simple moving average of $29.14. The firm has a market cap of $2.26 billion, a price-to-earnings ratio of -23.31 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to the consensus estimate of $63.55 million. On average, sell-side analysts anticipate that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in Urogen Pharma by 347.5% in the first quarter. AQR Capital Management LLC now owns 114,066 shares of the company's stock valued at $1,262,000 after acquiring an additional 88,577 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Urogen Pharma by 7.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company's stock valued at $258,000 after buying an additional 1,653 shares during the period. Jane Street Group LLC lifted its position in shares of Urogen Pharma by 94.3% during the 1st quarter. Jane Street Group LLC now owns 51,177 shares of the company's stock valued at $566,000 after buying an additional 24,839 shares during the last quarter. Cetera Investment Advisers bought a new position in shares of Urogen Pharma during the 2nd quarter worth $361,000. Finally, JPMorgan Chase & Co. grew its stake in shares of Urogen Pharma by 5.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 390,364 shares of the company's stock worth $5,348,000 after acquiring an additional 19,405 shares during the period. 91.29% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on URGN. The Goldman Sachs Group reissued a "neutral" rating and issued a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a report on Thursday, July 9th. TD Cowen raised their price objective on Urogen Pharma from $50.00 to $60.00 and gave the company a "buy" rating in a research note on Wednesday, August 5th. Guggenheim lifted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, HC Wainwright upped their target price on shares of Urogen Pharma from $45.00 to $75.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Urogen Pharma currently has an average rating of "Moderate Buy" and a consensus target price of $50.38.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra'anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company's lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source